LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Novartis AG

Geschlossen

117.96 0.28

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

117.5

Max

118.17

Schlüsselkennzahlen

By Trading Economics

Einkommen

786M

3.6B

Verkäufe

62M

14B

KGV

Branchendurchschnitt

18.292

51.198

EPS

2.28

Dividendenrendite

3.42

Gewinnspanne

26.476

Angestellte

75,883

EBITDA

643M

5.8B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-4.36% downside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.42%

2.40%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

13B

230B

Vorheriger Eröffnungskurs

117.68

Vorheriger Schlusskurs

117.96

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Novartis AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Mai 2025, 09:36 UTC

Wichtige Markttreiber

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30. Apr. 2025, 16:35 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30. Apr. 2025, 11:55 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30. Apr. 2025, 11:54 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Acquire Regulus in $1.7 Billion Deal

29. Apr. 2025, 07:09 UTC

Ergebnisse

Novartis Lifts Guidance After Profit, Sales Top Views -- Update

29. Apr. 2025, 05:36 UTC

Ergebnisse

Novartis Lifts Guidance After Profit, Sales Top Views

2. Juni 2025, 14:17 UTC

Market Talk

Novartis's Pluvicto Delivers Positive Results in Third Late-Stage Trial -- Market Talk

27. Mai 2025, 12:04 UTC

Akquisitionen, Fusionen, Übernahmen

Correct: Novartis Will Offer $7.00 in Cash Per Share

27. Mai 2025, 12:01 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Offer Will Expire on June 24

27. Mai 2025, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis Will Offer $0.001 Per Share

27. Mai 2025, 11:59 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Offer Is to Acquire All Outstanding Shares of Regulus Therapeutics's Common Stock

27. Mai 2025, 11:59 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Redwood Merger Sub Inc. Is an Indirect Wholly Owned Subsidiary of Novartis

27. Mai 2025, 11:58 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Redwood Merger Sub Inc. Has Commenced a Tender Offer

27. Mai 2025, 11:57 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis Announces Commencement of Tender Offer to Buy Regulus Therapeutics

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

30. Apr. 2025, 11:40 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30. Apr. 2025, 11:39 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Acquire Regulus in $1.7B Deal

30. Apr. 2025, 11:16 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Transaction Is Expected to Close in Second Half of 2025

30. Apr. 2025, 11:15 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30. Apr. 2025, 11:14 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30. Apr. 2025, 11:13 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Buy Regulus Therapeutics

29. Apr. 2025, 12:34 UTC

Market Talk
Ergebnisse

Novartis Solid Result Shifts Investor Focus to 2H -- Market Talk

29. Apr. 2025, 11:54 UTC

Market Talk
Ergebnisse

Correction to Novartis Market Talk

29. Apr. 2025, 11:47 UTC

Market Talk
Ergebnisse

Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk

29. Apr. 2025, 10:42 UTC

Market Talk
Ergebnisse

Novartis Surprises With Another Beat & Raise -- Market Talk

29. Apr. 2025, 10:16 UTC

Market Talk
Ergebnisse

Novartis's Guidance Lift Reflects Strong Sales -- Market Talk

29. Apr. 2025, 05:06 UTC

Ergebnisse

Novartis Had Seen Core Operating Profit to Grow at High Single to Low Double-Digit in 2025 at Constant Currencies

29. Apr. 2025, 05:06 UTC

Ergebnisse

Novartis Expects Core Operating Profit to Grow Low Double-Digit in 2025 at Constant Currencies

29. Apr. 2025, 05:05 UTC

Ergebnisse

Novartis Had Seen Sales Grow Mid- to High-Single Digit in 2025 at Constant Currencies

Peer-Vergleich

Kursveränderung

Novartis AG Prognose

Kursziel

By TipRanks

-4.36% Nachteil

12-Monats-Prognose

Durchschnitt 112.66 USD  -4.36%

Hoch 135.307 USD

Tief 88 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novartis AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

2

Buy

3

Halten

1

Sell

Technischer Score

By Trading Central

N/A / 112.63Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Strong Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.